Cargando…

Interferential therapy for chronic constipation in adults: The CON‐COUR randomizedcontrolled trial

BACKGROUND: Chronic constipation (CC) is a frequent condition, and the first‐line treatment includes dietary rules, the use of laxatives, and biofeedback for evacuation disorders. However, almost half of the patients are dissatisfied with their current treatment. We report the first double‐blind ran...

Descripción completa

Detalles Bibliográficos
Autores principales: Vitton, Veronique, Mion, François, Leroi, Anne‐Marie, Brochard, Charlène, Coffin, Benoit, Zerbib, Frank, Damon, Henri, Melchior, Chloé, Duboc, Henri, Queralto, Michel, Baumstarck, Karine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165323/
https://www.ncbi.nlm.nih.gov/pubmed/37186357
http://dx.doi.org/10.1002/ueg2.12373
_version_ 1785038245864669184
author Vitton, Veronique
Mion, François
Leroi, Anne‐Marie
Brochard, Charlène
Coffin, Benoit
Zerbib, Frank
Damon, Henri
Melchior, Chloé
Duboc, Henri
Queralto, Michel
Baumstarck, Karine
author_facet Vitton, Veronique
Mion, François
Leroi, Anne‐Marie
Brochard, Charlène
Coffin, Benoit
Zerbib, Frank
Damon, Henri
Melchior, Chloé
Duboc, Henri
Queralto, Michel
Baumstarck, Karine
author_sort Vitton, Veronique
collection PubMed
description BACKGROUND: Chronic constipation (CC) is a frequent condition, and the first‐line treatment includes dietary rules, the use of laxatives, and biofeedback for evacuation disorders. However, almost half of the patients are dissatisfied with their current treatment. We report the first double‐blind randomized multicenter trial assessing the effectiveness of transabdominal electrical stimulation by interferential therapy (IFT) in the treatment of CC in adults. METHODS: A prospective, multicenter, randomized, double‐blind, sham‐controlled, parallel‐group, phase 3 trial was conducted at 7 centers in France. The primary endpoint was 8‐week efficacy as defined by the number of complete spontaneous bowel movements during the last 4 weeks of the 8‐week stimulation period. Secondary endpoints included the evaluation of the effects of IFT on symptoms (Patient Assessment of Constipation Symptoms questionnair (PAC‐SYM)), quality of life (QOL) (Patient Assessment of Constipation Quality of Life), Colonic transit time (CTT), anorectal manometry, and patient satisfaction. RESULTS: The proportion of 8‐week responders was not significantly different between the two groups (73.2% in the IFT group vs. 67.1% in the sham group). After 8 weeks of stimulation, the mean overall PAC‐SYM score and the mean reduction in the overall PAC‐SYM score were significantly greater in the IFT group than in the sham group. No differences were observed concerning CTT, anorectal manometry, or patient satisfaction. CONCLUSIONS: Although the primary endpoint was not reached, IFT can significantly alleviate the symptoms and improve the QOL of CC patients. It can be assumed that new treatments require different modes of evaluation and that the assessment of patient‐reported outcomes may become a priority among therapeutic targets of CC. Trial registration number NCT02381665.
format Online
Article
Text
id pubmed-10165323
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-101653232023-05-09 Interferential therapy for chronic constipation in adults: The CON‐COUR randomizedcontrolled trial Vitton, Veronique Mion, François Leroi, Anne‐Marie Brochard, Charlène Coffin, Benoit Zerbib, Frank Damon, Henri Melchior, Chloé Duboc, Henri Queralto, Michel Baumstarck, Karine United European Gastroenterol J Neurogastroenterology BACKGROUND: Chronic constipation (CC) is a frequent condition, and the first‐line treatment includes dietary rules, the use of laxatives, and biofeedback for evacuation disorders. However, almost half of the patients are dissatisfied with their current treatment. We report the first double‐blind randomized multicenter trial assessing the effectiveness of transabdominal electrical stimulation by interferential therapy (IFT) in the treatment of CC in adults. METHODS: A prospective, multicenter, randomized, double‐blind, sham‐controlled, parallel‐group, phase 3 trial was conducted at 7 centers in France. The primary endpoint was 8‐week efficacy as defined by the number of complete spontaneous bowel movements during the last 4 weeks of the 8‐week stimulation period. Secondary endpoints included the evaluation of the effects of IFT on symptoms (Patient Assessment of Constipation Symptoms questionnair (PAC‐SYM)), quality of life (QOL) (Patient Assessment of Constipation Quality of Life), Colonic transit time (CTT), anorectal manometry, and patient satisfaction. RESULTS: The proportion of 8‐week responders was not significantly different between the two groups (73.2% in the IFT group vs. 67.1% in the sham group). After 8 weeks of stimulation, the mean overall PAC‐SYM score and the mean reduction in the overall PAC‐SYM score were significantly greater in the IFT group than in the sham group. No differences were observed concerning CTT, anorectal manometry, or patient satisfaction. CONCLUSIONS: Although the primary endpoint was not reached, IFT can significantly alleviate the symptoms and improve the QOL of CC patients. It can be assumed that new treatments require different modes of evaluation and that the assessment of patient‐reported outcomes may become a priority among therapeutic targets of CC. Trial registration number NCT02381665. John Wiley and Sons Inc. 2023-04-25 /pmc/articles/PMC10165323/ /pubmed/37186357 http://dx.doi.org/10.1002/ueg2.12373 Text en © 2023 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC on behalf of United European Gastroenterology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Neurogastroenterology
Vitton, Veronique
Mion, François
Leroi, Anne‐Marie
Brochard, Charlène
Coffin, Benoit
Zerbib, Frank
Damon, Henri
Melchior, Chloé
Duboc, Henri
Queralto, Michel
Baumstarck, Karine
Interferential therapy for chronic constipation in adults: The CON‐COUR randomizedcontrolled trial
title Interferential therapy for chronic constipation in adults: The CON‐COUR randomizedcontrolled trial
title_full Interferential therapy for chronic constipation in adults: The CON‐COUR randomizedcontrolled trial
title_fullStr Interferential therapy for chronic constipation in adults: The CON‐COUR randomizedcontrolled trial
title_full_unstemmed Interferential therapy for chronic constipation in adults: The CON‐COUR randomizedcontrolled trial
title_short Interferential therapy for chronic constipation in adults: The CON‐COUR randomizedcontrolled trial
title_sort interferential therapy for chronic constipation in adults: the con‐cour randomizedcontrolled trial
topic Neurogastroenterology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165323/
https://www.ncbi.nlm.nih.gov/pubmed/37186357
http://dx.doi.org/10.1002/ueg2.12373
work_keys_str_mv AT vittonveronique interferentialtherapyforchronicconstipationinadultstheconcourrandomizedcontrolledtrial
AT mionfrancois interferentialtherapyforchronicconstipationinadultstheconcourrandomizedcontrolledtrial
AT leroiannemarie interferentialtherapyforchronicconstipationinadultstheconcourrandomizedcontrolledtrial
AT brochardcharlene interferentialtherapyforchronicconstipationinadultstheconcourrandomizedcontrolledtrial
AT coffinbenoit interferentialtherapyforchronicconstipationinadultstheconcourrandomizedcontrolledtrial
AT zerbibfrank interferentialtherapyforchronicconstipationinadultstheconcourrandomizedcontrolledtrial
AT damonhenri interferentialtherapyforchronicconstipationinadultstheconcourrandomizedcontrolledtrial
AT melchiorchloe interferentialtherapyforchronicconstipationinadultstheconcourrandomizedcontrolledtrial
AT dubochenri interferentialtherapyforchronicconstipationinadultstheconcourrandomizedcontrolledtrial
AT queraltomichel interferentialtherapyforchronicconstipationinadultstheconcourrandomizedcontrolledtrial
AT baumstarckkarine interferentialtherapyforchronicconstipationinadultstheconcourrandomizedcontrolledtrial